Nektar Therapeutics
NKTR23.165USD
+0.205+0.89%
交易中 （美東）報價延遲15分鐘
287.41M總市值
虧損本益比TTM
關於 Nektar Therapeutics 公司
Nektar Therapeutics 是一家臨牀階段的生物技術公司。該公司專注於開發治療自身免疫和慢性炎症疾病中潛在免疫功能障礙的治療方法。在腫瘤學方面，該公司專注於開發基於靶向生物途徑的藥物，這些途徑可刺激和維持人體的免疫反應以對抗癌症。其主要候選產品 rezpegaldesleukin (REZPEG 或 NKTR-358) 是一種新型調節性 T 細胞刺激劑，目前正在進行兩項 2b 期臨牀試驗，一項針對特應性皮炎，一項針對斑禿。其產品線還包括臨牀前二價腫瘤壞死因子受體 II 型 (TNFR2) 抗體和雙特異性項目 NKTR-0165 和 NKTR-0166，以及改良的造血集落刺激因子 (CSF) 蛋白 NKTR-422。該公司還在幾項正在進行的臨牀試驗中對 NKTR-255 進行評估，NKTR-255 是一種試驗性的 IL-15 受體激動劑，旨在增強免疫系統抗癌的自然能力。
公司簡介
公司代碼NKTR
公司名稱Nektar Therapeutics
上市日期May 03, 1994
CEOMr. Howard W. Robin
員工數量61
證券類型Ordinary Share
年結日May 03
公司地址455 Mission Bay Boulevard South
城市SAN FRANCISCO
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編94158
電話18554826587
網址https://www.nektar.com/
公司代碼NKTR
上市日期May 03, 1994
CEOMr. Howard W. Robin
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Howard W. Robin
Mr. Howard W. Robin
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
63.40K
-2.38%
Dr. Jonathan Zalevsky, Ph.D.
Dr. Jonathan Zalevsky, Ph.D.
Senior Vice President, Chief Research and Development Officer
Senior Vice President, Chief Research and Development Officer
18.08K
-3.80%
Mr. Jeffrey Robert (Jeff) Ajer
Mr. Jeffrey Robert (Jeff) Ajer
Independent Director
Independent Director
2.28K
--
Dr. Diana M. Brainard, M.D.
Dr. Diana M. Brainard, M.D.
Independent Director
Independent Director
--
--
Mr. R. Scott Greer
Mr. R. Scott Greer
Independent Director
Independent Director
--
--
Corey Davis
Corey Davis
Managing Director
Managing Director
--
--
Mr. Robert B. (Rob) Chess
Mr. Robert B. (Rob) Chess
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Sandra A. Gardiner
Ms. Sandra A. Gardiner
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Mr. Mark A. Wilson, J.D.
Mr. Mark A. Wilson, J.D.
Senior Vice President, Chief Legal Officer
Senior Vice President, Chief Legal Officer
--
--
Mr. Roy A. Whitfield
Mr. Roy A. Whitfield
Lead Independent Director
Lead Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Howard W. Robin
Mr. Howard W. Robin
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
63.40K
-2.38%
Dr. Jonathan Zalevsky, Ph.D.
Dr. Jonathan Zalevsky, Ph.D.
Senior Vice President, Chief Research and Development Officer
Senior Vice President, Chief Research and Development Officer
18.08K
-3.80%
Mr. Jeffrey Robert (Jeff) Ajer
Mr. Jeffrey Robert (Jeff) Ajer
Independent Director
Independent Director
2.28K
--
Dr. Diana M. Brainard, M.D.
Dr. Diana M. Brainard, M.D.
Independent Director
Independent Director
--
--
Mr. R. Scott Greer
Mr. R. Scott Greer
Independent Director
Independent Director
--
--
Corey Davis
Corey Davis
Managing Director
Managing Director
--
--
收入明細
單位: USD更新時間: 7月6日 週日
單位: USD更新時間: 7月6日 週日
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
暫無數據
地區USD
名稱
營收
佔比
Rest of world
97.05M
98.60%
United States
1.38M
1.40%
業務
地區
暫無數據
股東統計
更新時間: 7月11日 週五
更新時間: 7月11日 週五
持股股東
股東類型
持股股東
持股股東
佔比
BVF Partners L.P.
7.66%
Millennium Management LLC
5.60%
BlackRock Institutional Trust Company, N.A.
5.24%
The Vanguard Group, Inc.
4.92%
Nantahala Capital Management, LLC
3.12%
Other
73.45%
持股股東
持股股東
佔比
BVF Partners L.P.
7.66%
Millennium Management LLC
5.60%
BlackRock Institutional Trust Company, N.A.
5.24%
The Vanguard Group, Inc.
4.92%
Nantahala Capital Management, LLC
3.12%
Other
73.45%
股東類型
持股股東
佔比
Hedge Fund
23.93%
Investment Advisor
23.87%
Investment Advisor/Hedge Fund
13.53%
Research Firm
1.08%
Individual Investor
0.96%
Family Office
0.25%
Bank and Trust
0.08%
Pension Fund
0.03%
Venture Capital
0.02%
Other
36.24%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
340
9.25M
55.51%
-2.77M
2025Q1
408
8.48M
68.15%
-4.47M
2024Q4
427
136.20M
73.84%
-69.28M
2024Q3
442
143.71M
78.07%
-57.20M
2024Q2
458
138.43M
75.38%
-54.08M
2024Q1
477
115.32M
62.79%
-91.21M
2023Q4
499
122.94M
64.45%
-94.24M
2023Q3
522
148.15M
77.94%
-68.45M
2023Q2
531
142.56M
75.34%
-88.27M
2023Q1
545
178.73M
94.47%
-35.40M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Millennium Management LLC
932.86K
5.6%
+780.28K
+511.36%
Jun 27, 2025
BlackRock Institutional Trust Company, N.A.
873.88K
5.24%
-15.04K
-1.69%
Mar 31, 2025
The Vanguard Group, Inc.
820.65K
4.92%
-1.22K
-0.15%
Mar 31, 2025
Nantahala Capital Management, LLC
519.27K
3.12%
-1.40K
-0.27%
Mar 31, 2025
Acadian Asset Management LLC
486.78K
2.92%
+6.71K
+1.40%
Mar 31, 2025
Eventide Asset Management, LLC
443.33K
2.66%
--
--
Mar 31, 2025
PRIMECAP Management Company
356.97K
2.14%
-12.39K
-3.35%
Mar 31, 2025
Renaissance Technologies LLC
313.45K
1.88%
+52.73K
+20.23%
Mar 31, 2025
Almitas Capital LLC
307.39K
1.84%
+246.04K
+401.06%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Invesco NASDAQ Future Gen 200 ETF
1.08%
Simplify Health Care ETF
1.03%
Invesco RAFI US 1500 Small-Mid ETF
0.03%
iShares Micro-Cap ETF
0.02%
iShares Russell 2000 Value ETF
0.01%
Schwab U.S. Small-Cap ETF
0.01%
iShares Biotechnology ETF
0%
ProShares Hedge Replication ETF
0%
Proshares Ultra Russell 2000
0%
ProShares Ultra Nasdaq Biotechnology
0%
查看更多
Invesco NASDAQ Future Gen 200 ETF
佔比1.08%
Simplify Health Care ETF
佔比1.03%
Invesco RAFI US 1500 Small-Mid ETF
佔比0.03%
iShares Micro-Cap ETF
佔比0.02%
iShares Russell 2000 Value ETF
佔比0.01%
Schwab U.S. Small-Cap ETF
佔比0.01%
iShares Biotechnology ETF
佔比0%
ProShares Hedge Replication ETF
佔比0%
Proshares Ultra Russell 2000
佔比0%
ProShares Ultra Nasdaq Biotechnology
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
